Risks and management of hypertension in cancer patients undergoing targeted therapy: a review.

ABSTRACT:

Background

Rapid progress over the last decade has added numerous agents targeting specific cellular signaling pathways to the treatment armamentarium for advanced cancer. However, many of these agents can cause hypertension resulting in major adverse cardiovascular event.

Methods and results

A systematic literature search was performed on the databases PubMed and Google Scholar for papers published in English until December 2020. This review summarizes the risk, mechanism, diagnosis, and management of hypertension in cancer patients undergoing targeted therapy. The risk and pathogenesis of hypertension vary widely with different classes of targeted agents. Currently there is a paucity of data investigating optimal management of hypertension with targeted therapy. A practica

SUBMITTER: Zhu X 

PROVIDER: S-EPMC9107678 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature